Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a smartphone app bridge the gap between primary care and addiction treatment?

NCT ID NCT06743282

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times

Summary

This study from Mayo Clinic tests whether a smartphone app called Senyo Health can help connect people with substance use disorders to treatment through their primary care doctor. Sixty participants will use the app for 12 weeks, which includes therapy modules, weekly check-ins with a care manager, and monthly urine tests. The goal is to understand what helps or hinders this digital approach, not to prove it works as a treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUBSTANCE USE DISORDERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Senyo Health app (behavioral intervention with therapy modules and care manager check-ins)

What this could lead to

If successful, this could show that a digital app helps connect primary care patients to substance use treatment more effectively.

What could go wrong

This is a small, early-stage study (60 people) focused on feasibility and barriers, not a large trial testing effectiveness. Results may not apply broadly.

Conditions

The condition(s) this trial relates to.

substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.